Bristol-Myers Squibb Company (BMY)
Return on equity (ROE)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 7,053,000 | -8,948,000 | 8,025,000 | 6,327,000 | 6,994,000 |
| Total stockholders’ equity | US$ in thousands | 18,473,000 | 16,335,000 | 29,430,000 | 31,061,000 | 35,946,000 |
| ROE | 38.18% | -54.78% | 27.27% | 20.37% | 19.46% |
December 31, 2025 calculation
ROE = Net income ÷ Total stockholders’ equity
= $7,053,000K ÷ $18,473,000K
= 38.18%
Peer comparison
Dec 31, 2025
Company name
Symbol
ROE
Bristol-Myers Squibb Company
BMY
38.18%
AbbVie Inc
ABBV
—
Amgen Inc
AMGN
89.06%
Biogen Inc
BIIB
7.08%
Eli Lilly and Company
LLY
77.78%
Gilead Sciences Inc
GILD
—
Johnson & Johnson
JNJ
32.87%
Merck & Company Inc
MRK
35.17%
Organon & Co
OGN
20.64%
Pfizer Inc
PFE
8.35%